Fertility drugs and cancer: a guideline

Samantha Pfeifer, Samantha Butts, Daniel Dumesic, Gregory Fossum, Clarisa Gracia, Andrew La Barbera, Jennifer Mersereau, Randall Odem, Richard Paulson, Alan Penzias, Margareta Pisarska, Robert Rebar, Richard Reindollar, Mitchell Rosen, Jay Sandlow, Michael Vernon, Eric Widra

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Methodological limitations in studying the association between the use of fertility drugs and cancer include the inherent increased risk of cancer in women who never conceive, the low incidence of most of these cancers, and that the age of diagnosis of cancer typically is many years after fertility drug use. Based on available data, there does not appear to be a meaningful increased risk of invasive ovarian cancer, breast cancer, or endometrial cancer following the use of fertility drugs. Several studies have shown a small increased risk of borderline ovarian tumors; however, there is insufficient consistent evidence that a particular fertility drug increases the risk of borderline ovarian tumors, and any absolute risk is small. Given the available literature, patients should be counseled that infertile women may be at an increased risk of invasive ovarian, endometrial, and breast cancer; however, use of fertility drugs does not appear to increase this risk.

Original languageEnglish
Pages (from-to)1617-1626
Number of pages10
JournalFertility and Sterility
Volume106
Issue number7
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint Dive into the research topics of 'Fertility drugs and cancer: a guideline'. Together they form a unique fingerprint.

Cite this